Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Themis Bioscience

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 11, 2020

            Details:

            Themis and ABL Europe have signed an agreement under which ABL will manufacture Themis' vaccine candidate in preparation for clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NK cell therapy,Antibody recruiting molecule

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kleo Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 31, 2020

            Details:

            Kleo's first non-oncology application of its antibody recruiting molecule (ARM™) to be tested in combination with GCLC'S NK cells as a potential COVID-19 therapeutic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): siRNAs

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 20, 2020

            Details:

            OliX has confirmed that their siRNAs show highly efficient knockdown of the viral RNA sequences through in vitro assay.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DWN12088

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 19, 2020

            Details:

            Daewoong Pharmaceuticals is developing “DWN12088,” a candidate material for the world's first new oral drug for pulmonary fibrosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Virus suppressing factor

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            ImmuneMed said the company and Seoul National University Hospital have won the government’s approval for Virus Suppressing Factor as the treatment for new coronavirus patients.